NASDAQ · XRTX
Healthcare · Biotechnology
$1.06
Up+$0.14 (+15.20%)
Updated Oct 27, 2026, 7:05 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · XRTX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
XRTX closed at $1.06 after 21 trading sessions, down 38.01% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $0.90 | $1.14 | $0.83 | $1.06 | 120.71K |
| Oct 23, 2026 | $0.95 | $0.95 | $0.915 | $0.9201 | 20.23K |
| Oct 22, 2026 | $0.9851 | $0.9851 | $0.91 | $0.9688 | 24.72K |
| Oct 21, 2026 | $0.9687 | $1.05 | $0.9002 | $0.9301 | 72.29K |
| Oct 20, 2026 | $0.99 | $1.04 | $0.92 | $0.9555 | 87.11K |
| Oct 19, 2026 | $1.22 | $1.24 | $0.9901 | $1.01 | 130.1K |
| Oct 16, 2026 | $1.39 | $1.4162 | $1.21 | $1.24 | 95.83K |
| Oct 15, 2026 | $1.53 | $1.54 | $1.41 | $1.42 | 127.19K |
| Oct 14, 2026 | $1.60 | $1.71 | $1.56 | $1.56 | 79.48K |
| Oct 13, 2026 | $1.62 | $1.73 | $1.51 | $1.68 | 177.6K |
| Oct 12, 2026 | $1.40 | $1.90 | $1.39 | $1.72 | 1.76M |
| Oct 9, 2026 | $2.05 | $2.0795 | $1.36 | $1.41 | 18.65M |
| Oct 8, 2026 | $1.75 | $1.90 | $1.72 | $1.85 | 10.68M |
| Oct 7, 2026 | $1.73 | $1.75 | $1.69 | $1.745 | 21.73K |
| Oct 6, 2026 | $1.75 | $1.7884 | $1.71 | $1.73 | 40.94K |
| Oct 5, 2026 | $1.73 | $1.73 | $1.69 | $1.70 | 8.94K |
| Oct 2, 2026 | $1.7169 | $1.7946 | $1.70 | $1.7142 | 4.48K |
| Oct 1, 2026 | $1.69 | $1.75 | $1.69 | $1.73 | 22.08K |
| Sep 30, 2026 | $1.70 | $1.72 | $1.69 | $1.69 | 26.08K |
| Sep 29, 2026 | $1.70 | $1.74 | $1.69 | $1.70 | 71.43K |
| Sep 28, 2026 | $1.69 | $1.7414 | $1.69 | $1.71 | 30.01K |
The latest Smart Investors Daily articles mentioning XRTX.
Company
Market Activity
Research & News
XRTX research
Company profile and research snapshot.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 8, 2023 | ALLIANCE GLOBAL PARTNERS | Buy | — |
| May 7, 2023 | ALLIANCE GLOBAL PARTNERS | Buy | — |
| Apr 10, 2023 | ALLIANCE GLOBAL PARTNERS | Buy | — |
| Apr 22, 2022 | Alliance Global Partbers | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 12, 2026
Gainers Mobile-health Network (NASDAQ:MNDR) stock rose 370.0% to $4.0 during Monday's regular session. The market value of their outstanding shares is at $1.0 million. XORTX Therapeutics (NASDAQ:XRTX) shares moved
Benzinga · Oct 9, 2026
XORTX Therapeutics shares climb 22.16% after hours as company advances plans for a Canadian gout drug trial.
Yahoo · Oct 8, 2026
● Clinical Trial Application planned for filing with Health Canada, extending the Company’s international regulatory strategy for gout program XRx-026 ● CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide an outline of its anticipated Clinical Trial Application (“CTA”) submiss
Yahoo · Sep 18, 2026
Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, outlines its anticipated Investigational New Drug applica
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XRTX.
No results
No recent SID articles mention XRTX.
